Cargando…
Incidence of acquired thrombotic thrombocytopenic purpura in Germany: a hospital level study
BACKGROUND: Acquired thrombotic thrombocytopenic Purpura (aTTP) is a life-threatening ultra-orphan disease with a reported annual incidence between 1.5 and 6.0 cases per million in Europe and mainly affecting otherwise young and healthy adults aged 40 years on average. The goal of this study was to...
Autores principales: | , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6858672/ https://www.ncbi.nlm.nih.gov/pubmed/31730475 http://dx.doi.org/10.1186/s13023-019-1240-0 |
_version_ | 1783471000568987648 |
---|---|
author | Miesbach, Wolfgang Menne, Jan Bommer, Martin Schönermarck, Ulf Feldkamp, Thorsten Nitschke, Martin Westhoff, Timm H. Seibert, Felix S. Woitas, Rainer Sousa, Rui Wolf, Michael Walzer, Stefan Schwander, Björn |
author_facet | Miesbach, Wolfgang Menne, Jan Bommer, Martin Schönermarck, Ulf Feldkamp, Thorsten Nitschke, Martin Westhoff, Timm H. Seibert, Felix S. Woitas, Rainer Sousa, Rui Wolf, Michael Walzer, Stefan Schwander, Björn |
author_sort | Miesbach, Wolfgang |
collection | PubMed |
description | BACKGROUND: Acquired thrombotic thrombocytopenic Purpura (aTTP) is a life-threatening ultra-orphan disease with a reported annual incidence between 1.5 and 6.0 cases per million in Europe and mainly affecting otherwise young and healthy adults aged 40 years on average. The goal of this study was to assess the incidence of aTTP in Germany. METHODS: A systematic review was performed to determine the published evidence on the aTTP epidemiology in Germany. To obtain additional evidence on the proportion of aTTP cases within the national Thrombotic Microangiopathy (TMA) population a hospital-level study was performed, using a retrospective data collection approach. Diagnosis of aTTP was confirmed if ADAMTS13 level were < 10% and/or the medical records explicitly mentioned aTTP diagnosis. The aggregated hospital data were then projected to the national level using logistic regression techniques. RESULTS: The systematic literature search did not provide incidence estimates of aTTP in Germany. Eight centers (≈27% of the top 30 TMA hospitals) delivered data according to a predefined data collection form. On average (year 2014–2016) a total number of 172 aTTP episodes per year was projected (95% confidence interval [95%CI]: 132–212). The majority were newly diagnosed aTTP cases (n = 121; 95%CI: 105–129), and 51 were recurrent aTTP cases (95%CI: 27–84). The average annual projected incidence (year 2014–2016) of aTTP episodes was 2.10 per million inhabitants in Germany (95%CI: 1.60–2.58). CONCLUSIONS: The determined annual incidence of newly diagnosed aTTP cases and the overall annual incidence of aTTP episodes in Germany confirm the ultra-orphan character of aTTP. An external validation against international registries (France, UK and USA) shows that our findings are quite comparable with those international incidence rates. |
format | Online Article Text |
id | pubmed-6858672 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-68586722019-11-29 Incidence of acquired thrombotic thrombocytopenic purpura in Germany: a hospital level study Miesbach, Wolfgang Menne, Jan Bommer, Martin Schönermarck, Ulf Feldkamp, Thorsten Nitschke, Martin Westhoff, Timm H. Seibert, Felix S. Woitas, Rainer Sousa, Rui Wolf, Michael Walzer, Stefan Schwander, Björn Orphanet J Rare Dis Research BACKGROUND: Acquired thrombotic thrombocytopenic Purpura (aTTP) is a life-threatening ultra-orphan disease with a reported annual incidence between 1.5 and 6.0 cases per million in Europe and mainly affecting otherwise young and healthy adults aged 40 years on average. The goal of this study was to assess the incidence of aTTP in Germany. METHODS: A systematic review was performed to determine the published evidence on the aTTP epidemiology in Germany. To obtain additional evidence on the proportion of aTTP cases within the national Thrombotic Microangiopathy (TMA) population a hospital-level study was performed, using a retrospective data collection approach. Diagnosis of aTTP was confirmed if ADAMTS13 level were < 10% and/or the medical records explicitly mentioned aTTP diagnosis. The aggregated hospital data were then projected to the national level using logistic regression techniques. RESULTS: The systematic literature search did not provide incidence estimates of aTTP in Germany. Eight centers (≈27% of the top 30 TMA hospitals) delivered data according to a predefined data collection form. On average (year 2014–2016) a total number of 172 aTTP episodes per year was projected (95% confidence interval [95%CI]: 132–212). The majority were newly diagnosed aTTP cases (n = 121; 95%CI: 105–129), and 51 were recurrent aTTP cases (95%CI: 27–84). The average annual projected incidence (year 2014–2016) of aTTP episodes was 2.10 per million inhabitants in Germany (95%CI: 1.60–2.58). CONCLUSIONS: The determined annual incidence of newly diagnosed aTTP cases and the overall annual incidence of aTTP episodes in Germany confirm the ultra-orphan character of aTTP. An external validation against international registries (France, UK and USA) shows that our findings are quite comparable with those international incidence rates. BioMed Central 2019-11-15 /pmc/articles/PMC6858672/ /pubmed/31730475 http://dx.doi.org/10.1186/s13023-019-1240-0 Text en © The Author(s). 2019 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
spellingShingle | Research Miesbach, Wolfgang Menne, Jan Bommer, Martin Schönermarck, Ulf Feldkamp, Thorsten Nitschke, Martin Westhoff, Timm H. Seibert, Felix S. Woitas, Rainer Sousa, Rui Wolf, Michael Walzer, Stefan Schwander, Björn Incidence of acquired thrombotic thrombocytopenic purpura in Germany: a hospital level study |
title | Incidence of acquired thrombotic thrombocytopenic purpura in Germany: a hospital level study |
title_full | Incidence of acquired thrombotic thrombocytopenic purpura in Germany: a hospital level study |
title_fullStr | Incidence of acquired thrombotic thrombocytopenic purpura in Germany: a hospital level study |
title_full_unstemmed | Incidence of acquired thrombotic thrombocytopenic purpura in Germany: a hospital level study |
title_short | Incidence of acquired thrombotic thrombocytopenic purpura in Germany: a hospital level study |
title_sort | incidence of acquired thrombotic thrombocytopenic purpura in germany: a hospital level study |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6858672/ https://www.ncbi.nlm.nih.gov/pubmed/31730475 http://dx.doi.org/10.1186/s13023-019-1240-0 |
work_keys_str_mv | AT miesbachwolfgang incidenceofacquiredthromboticthrombocytopenicpurpuraingermanyahospitallevelstudy AT mennejan incidenceofacquiredthromboticthrombocytopenicpurpuraingermanyahospitallevelstudy AT bommermartin incidenceofacquiredthromboticthrombocytopenicpurpuraingermanyahospitallevelstudy AT schonermarckulf incidenceofacquiredthromboticthrombocytopenicpurpuraingermanyahospitallevelstudy AT feldkampthorsten incidenceofacquiredthromboticthrombocytopenicpurpuraingermanyahospitallevelstudy AT nitschkemartin incidenceofacquiredthromboticthrombocytopenicpurpuraingermanyahospitallevelstudy AT westhofftimmh incidenceofacquiredthromboticthrombocytopenicpurpuraingermanyahospitallevelstudy AT seibertfelixs incidenceofacquiredthromboticthrombocytopenicpurpuraingermanyahospitallevelstudy AT woitasrainer incidenceofacquiredthromboticthrombocytopenicpurpuraingermanyahospitallevelstudy AT sousarui incidenceofacquiredthromboticthrombocytopenicpurpuraingermanyahospitallevelstudy AT wolfmichael incidenceofacquiredthromboticthrombocytopenicpurpuraingermanyahospitallevelstudy AT walzerstefan incidenceofacquiredthromboticthrombocytopenicpurpuraingermanyahospitallevelstudy AT schwanderbjorn incidenceofacquiredthromboticthrombocytopenicpurpuraingermanyahospitallevelstudy |